Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)

Summary

  • Most studies have suggested that the association between the early loss of BMD and the start of ART appears to occur regardless of ARV agent or class[Tebas 2007; Brown 2009; van Vonderen 2009]
  • The ANRS 143/NEAT 100 study demonstrated that use of NRTI-containing vs sparing therapy was associated with greater likelihood of BMD loss over 96 weeks
  • A bone substudy of ACTG 5142 demonstrated that the initiation of ART was associated with a decrease in total body bone mass of 2% to 4% that was independent of the regimen selected and stabilized by Week 48

    Action required